Top officials at FDA are signaling that the combination products review process is ripe for reform and the 2017 user fee reauthorizations will offer a good opportunity to make needed changes.
Companies and FDA each have frustrations with mismatches between drug and device regulations and with communication challenges between the product centers that lead to inefficiencies.